Smoking Status Not Associated With TNF Inhibition Discontinuation in axSpA
Researchers examined the effect of smoking on all-cause and cause-specific discontinuation of tumor necrosis factor inhibition in patients with axial spondyloarthritis.
Tumor Necrosis Factor Inhibitors
Machine Learning Model Can Predict Anti-TNF Drug Response in RA
The model improves anti-TNF drug selection and the effect of genetic markers across multiple cohorts.
TNFi Therapy Did Not Prevent Joint Ankylosis in Young Patients With Spondyloarthritis
TNFi therapy failed to prevent the development of joint ankylosis despite a substantial reduction in inflammation with TNFi therapy.
Risk for Peripheral Neuropathy Assessed in Patients With Rheumatic Diseases
Researchers assessed the risk for peripheral neuropathy with TNFi in patients with rheumatic diseases.
TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis
Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.
Continuing, Switching TNFi After Serious Infection Reduces Likelihood of Recurrent Infection
Patients who continued or switched their TNF inhibitor after a serious infection had a lower risk for recurrent infection compared with those who stopped the drug.
TNFi Discontinuation During Pregnancy Linked to Postpartum Inflammatory Disease Flares
Researchers observed a higher peri- and postpartum flare rate in mothers who discontinued TNFi during the first trimester.
Low Tuberculosis Screening Rates Observed Among Patients Starting TNFis
Only about half of patients who started TNFi therapy were screened for tuberculosis prior to therapy initiation.
Next post in EULAR 2018 Coverage
